Ascendis Pharma A/s (ASND) trailing twelve month income statement covering six trailing twelve month periods to September 30, 2018, as reported to the SEC. This statement has 2 line items across 6 periods.
An income statement shows what a company sold and what it cost to run the business, ending with the profit left over.
| Sep'18 | Jun'18 | Mar'18 | Dec'17 | Sep'17 | Jun'17 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Other comprehensive income / (loss) | |||||||||||||||||||||
Items that may be reclassified subsequently to profit or loss: | |||||||||||||||||||||
Number of shares used for calculation (basic and diluted) | |||||||||||||||||||||
41,888 | 41,650 | 38,699 | 36,966 | 32,607 | 32,502 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Number of shares used for calculation (basic and diluted) | 41,888 | 41,650 | 38,699 | 36,966 | 32,607 | 32,502 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Number of shares used for calculation (diluted) | |||||||||||||||||||||
- | 41,650 | - | - | - | 32,502 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Number of shares used for calculation (diluted) | - | 41,650 | - | - | - | 32,502 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||